Agilent Announces New Organizational Structure to Support its Market-Focused Strategy
Agilent Technologies (NYSE: A) announced a major organizational restructuring to enhance market focus and customer centricity. The company introduced three new business groups: Life Sciences and Diagnostics Markets Group (LDG) representing 38% of revenue, Applied Markets Group (AMG) at 20%, and Agilent CrossLab Group (ACG) at 42%. Simon May will lead LDG, Mike Zhang will head AMG, and Angelica Riemann will continue leading ACG. The restructuring aims to improve collaboration and execution across divisions. The company will begin reporting under the new structure from Q1 2025.
Agilent Technologies (NYSE: A) ha annunciato una significativa ristrutturazione organizzativa per migliorare il focus sul mercato e la centralità del cliente. L'azienda ha introdotto tre nuovi gruppi aziendali: il Life Sciences and Diagnostics Markets Group (LDG) che rappresenta il 38% del fatturato, il Applied Markets Group (AMG) al 20%, e il Agilent CrossLab Group (ACG) al 42%. Simon May guiderà il LDG, Mike Zhang dirigerà l'AMG e Angelica Riemann proseguirà alla guida dell'ACG. La ristrutturazione mira a migliorare la collaborazione e l'esecuzione tra le divisioni. L'azienda inizierà a riferire secondo la nuova struttura dal primo trimestre del 2025.
Agilent Technologies (NYSE: A) anunció una importante reestructuración organizativa para mejorar el enfoque en el mercado y la centralidad del cliente. La compañía presentó tres nuevos grupos de negocios: el Life Sciences and Diagnostics Markets Group (LDG) que representa el 38% de los ingresos, el Applied Markets Group (AMG) con un 20%, y el Agilent CrossLab Group (ACG) que abarca el 42%. Simon May liderará el LDG, Mike Zhang estará al frente del AMG, y Angelica Riemann continuará dirigiendo el ACG. La reestructuración tiene como objetivo mejorar la colaboración y la ejecución entre divisiones. La compañía comenzará a informar bajo la nueva estructura a partir del primer trimestre de 2025.
아질런트 테크놀로지스 (NYSE: A)는 시장 집중도와 고객 중심성을 강화하기 위한 주요 조직 개편을 발표했습니다. 회사는 수익의 38%를 차지하는 생명 과학 및 진단 시장 그룹 (LDG), 20%를 차지하는 응용 시장 그룹 (AMG), 42%를 차지하는 아질런트 크로스랩 그룹 (ACG)의 세 가지 새로운 사업 그룹을 도입했습니다. Simon May가 LDG를 이끌고, Mike Zhang이 AMG를 담당하며, Angelica Riemann이 ACG를 계속 이끌 것입니다. 이번 구조 개편은 부서 간 협력 및 실행을 개선하는 것을 목표로 하고 있습니다. 회사는 2025년 1분기부터 새로운 구조 하에서 보고를 시작할 것입니다.
Agilent Technologies (NYSE: A) a annoncé une réorganisation majeure pour renforcer son orientation vers le marché et sa centration sur le client. L'entreprise a introduit trois nouveaux groupes d'activités : le Life Sciences and Diagnostics Markets Group (LDG), représentant 38 % des revenus, le Applied Markets Group (AMG), avec 20 %, et le Agilent CrossLab Group (ACG), à 42 %. Simon May dirigera le LDG, Mike Zhang sera à la tête de l'AMG et Angelica Riemann continuera à diriger l'ACG. Cette réorganisation vise à améliorer la collaboration et l'exécution entre les départements. L'entreprise commencera à faire rapport selon la nouvelle structure à partir du premier trimestre 2025.
Agilent Technologies (NYSE: A) hat eine umfassende organisatorische Umstrukturierung angekündigt, um den Markt- und Kundenfokus zu verbessern. Das Unternehmen hat drei neue Geschäftsgruppen eingeführt: die Life Sciences and Diagnostics Markets Group (LDG), die 38% des Umsatzes ausmacht, die Applied Markets Group (AMG) mit 20% und die Agilent CrossLab Group (ACG) mit 42%. Simon May wird das LDG leiten, Mike Zhang wird das AMG anführen und Angelica Riemann wird weiterhin das ACG leiten. Die Umstrukturierung zielt darauf ab, die Zusammenarbeit und Umsetzung zwischen den Abteilungen zu verbessern. Das Unternehmen wird beginnen, ab dem ersten Quartal 2025 unter der neuen Struktur zu berichten.
- Clear market segmentation with defined revenue distribution across divisions
- Strategic reorganization aimed at improving operational efficiency
- Experienced leadership appointments with strong industry backgrounds
- Transition period could cause temporary operational disruptions
- Restructuring may incur additional costs
- Retirement of experienced executive Phil Binns in April 2025
Insights
This organizational restructuring represents a significant strategic shift for Agilent, consolidating operations into three market-focused segments: Life Sciences and Diagnostics (
The reorganization aligns with industry trends toward integrated solutions and specialized market focus. By consolidating related business units, Agilent can better leverage cross-selling opportunities and streamline R&D investments. The appointment of experienced leaders, particularly Simon May from Bio-Rad Laboratories, brings valuable industry expertise to drive growth in the important life sciences segment.
While organizational restructuring often carries execution risks and temporary disruptions, Agilent's methodical approach with planned financial reporting transitions and leadership support suggests a well-planned implementation. Investors should monitor Q1 2025 results for early indicators of the restructuring's effectiveness.
“This is an important step in our transformation to become a nimbler company that puts our customers and our markets first,” said Agilent President and CEO Padraig McDonnell. “It builds on Agilent’s legacy of success and evolves our business to further strengthen our performance, sharpen our focus, and accelerate our market-focused solutions.”
The New Structure
The new structure organizes Agilent’s businesses according to its end markets and customers. It will enable closer collaboration among the business groups and better execution on cross-division, customer-first priorities.
Below are the three new business groups:
-
Life Sciences and Diagnostics Markets Group (LDG) represents
38% 1 of Agilent’s revenue and is primarily focused on Agilent’s pharma, biopharma, clinical, and diagnostics end markets.
LDG provides a comprehensive portfolio of leading technology platforms and solutions to serve Agilent customers’ value chain — including research and discovery, development and scale-up, production of therapeutics, and development of critical cancer diagnostics.
LDG includes liquid chromatography and mass spectrometry instrument platforms, cell and biomolecular analysis, specialized CDMO services, pathology, companion diagnostics, and genomics.
-
Applied Markets Group (AMG) represents
20% 2 of Agilent’s revenue and is primarily focused on the food, environmental, forensics, chemicals, and advanced materials markets.
AMG will focus on growing Agilent’s leadership in these markets and accelerating growth in new areas of the market.
AMG includes gas chromatography and mass spectrometry, spectroscopy, and vacuum technology platforms.
-
Agilent CrossLab Group (ACG) represents
42% 3 of Agilent’s revenue and is focused on supporting our customers in all our end markets.
ACG will accelerate and strengthen customer connections across all Agilent end markets. The group is uniquely positioned to leverage its comprehensive portfolio and capabilities. This will further enhance the installed base of instruments with targeted workflows and applications that drive critical outcomes and productivity in labs.
ACG includes services, software and informatics, automation, and consumables.
Business Group Leadership
- Simon May will serve as president of LDG. Simon recently served as president of the Diagnostics and Genomics Group (DGG). Prior to joining Agilent earlier this year, Simon was executive vice president and president of the Life Science Group at Bio-Rad Laboratories.
- Mike Zhang has been promoted to president of AMG. Most recently, Mike was vice president and general manager of our gas chromatography and mass spectrometry product line. Mike is a 22-year veteran of Agilent. Phil Binns, former president of the Life Sciences and Applied Markets group (LSAG), will retire in April 2025 after supporting the transition to the new business group structure.
- Angelica Riemann will continue to serve as president of ACG. Angelica is a 25-year veteran of Agilent and prior to her current role she served as vice president and general manager of ACG’s Services Division.
Agilent Analyst and Investor Day
Agilent will share additional details about the company’s market-focused, customer-first enterprise strategy and transformation at its Analyst and Investor Day on Dec. 17, 2024. The event will be webcast and available for replay afterwards. See details here.
Reporting Changes
Later today, Agilent will release fourth-quarter fiscal 2024 financial results. These results will be reported under the existing fiscal year 2024 organizational structure.
Agilent’s first-quarter 2025 results will be reported under the new organizational structure. Agilent will issue an 8-K before the company’s Analyst and Investor Day with a recast of the previous three years of financial reporting to reflect the new structure. Agilent will release a recast 10-K reflecting the new structure in March 2025.
Forward Looking Statement
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding Agilent’s new organizational structure, operational transformation and market-focused, customer-centric strategy, including the effects on Agilent’s performance, focus and market-focused solutions; growth; leadership; collaboration and execution; customer connections and leveraging Agilent’s portfolio and capabilities. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing; the ability to meet and achieve the benefits of its new organizational structure, operational transformation and market-focused strategy and otherwise successfully adapt to continuing changes in business conditions; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2024. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of
___________________
1 Revenue percentage estimates for each group are based on fiscal year 2024 revenue.
2 ibid.
3 ibid.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125449691/en/
Investor Contact:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com
Media Contact:
Sarah Litton
+1 408 361 0405
sarah.litton@agilent.com
Source: Agilent Technologies Inc.
FAQ
What are the three new business groups in Agilent's restructuring?
When will Agilent (NYSE: A) begin reporting under its new organizational structure?
Who are the new leaders of Agilent's restructured business groups?
When is Agilent's Analyst and Investor Day 2024?
